{
    "url_original": "https://www.wsj.com/articles/medicare-to-pay-for-biogens-new-alzheimers-drug-in-clinical-trial-patients-11641937588?mod=business_lead_pos4",
    "url": "medicare-to-pay-for-biogens-new-alzheimers-drug-in-clinical-trial-patients-11641937588",
    "title": "Medicare to Pay for Biogen’s New Alzheimer’s Drug in Clinical-Trial Patients",
    "sub_head": "The Centers for Medicare and Medicaid Services said it will cover the cost of the drug Aduhelm, but as part of further clinical testing",
    "category_1": "Business",
    "category_2": "Health Care",
    "image_1_url": "https://images.wsj.net/im-465987?width=860&height=573",
    "image_1": "im-465987.jpg",
    "time": "2022-01-11 17:35:00",
    "body": "Medicare officials said they would cover  Biogen Inc.’s  controversial Alzheimer’s disease drug Aduhelm on the condition that patients are in clinical trials and have early-stage symptoms.<br />The clinical trials are intended to gather evidence on the drug’s safety and effectiveness and would apply to similar drugs if they are approved, the Centers for Medicare and Medicaid said in a proposed policy issued Tuesday."
}